Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis

This publication has 88 references indexed in Scilit:

• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
  The Lancet Oncology, 2012
• Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
  The Lancet Oncology, 2012
• The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
  BMJ, 2011
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
  The Lancet Oncology, 2011
• Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
  Supportive Care in Cancer, 2011
• The BUGS project: Evolution, critique and future directions
  Statistics in Medicine, 2009
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
  New England Journal of Medicine, 2009
• Epidermal growth factor receptor mutations in lung cancer
  Nature Reviews Cancer, 2007
• Combination of direct and indirect evidence in mixed treatment comparisons
  Statistics in Medicine, 2004
• Measuring inconsistency in meta-analyses
  BMJ, 2003